Effectiveness of Thrombopoietin-receptor Agonists in the Treatment of Refractory Immune Thrombocytopenia Associated to Systemic Lupus Erythematosus

Article Figures & Data

Table 1.

Characteristics of the patients with SLE-associated refractory immune thrombocytopenia who were treated with thrombopoietin-receptor agonists.

Case (ref)	Age, yrs	Sex	Previous Treatments	Thrombopoietin-receptor Agonist	Dose	Response	Time to Response	Adverse Events
#1 (PC)	69	F	CS, IVIG, splenectomy, RTX	Eltrombopag	25 mg/day	Yes	2 weeks	No
#2 (PC)	39	F	CS, IVIG, CYC, azathioprine, RTX	Romiplostim	2 mcg/kg/week, further increased to 7 μg/kg/week	Yes	2 weeks	No
#3 (6)	44	M	CS, IVIG, azathioprine, RTX, CYC	Romiplostim	2 mcg/kg/week	Yes	3 weeks	No
#4 (7)	34	F	CS, IVIG, RTX, CYC	Romiplostim (previously eltrombopag without response)	3 mcg/kg/week	Yes	6 days	No
#5 (8)	19	F	CS, IVIG, RTX	Romiplostim	NS	Yes	NS	Kidney-limited thrombotic microangiopathy
#6 (9)	55	F	CS, RTX, CSA	Eltrombopag	50 mg/day	Yes	2 weeks	No
#7 (10)	NS	NS	NS	NS	NS	No	NS	NS

PC: present case; CS: corticosteroids; IVIG: intravenous immunoglobulin; RTX: rituximab; CYC: cyclophosphamide; CSA: cyclosporine; NS: not specified.